PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

  • End date
    Jan 30, 2023
  • participants needed
  • sponsor
    LegoChem Biosciences, Inc
Updated on 16 November 2021


This trial is to describe the safety, tolerability and exposure-toxicity relationship of Depazolid given over 16 weeks, in combination with standard-dose Bedaquiline, Delamanid and Moxifloxacin, compared to standard-dose Bedaquiline, Delamanid and Moxifloxacin alone


This will be an open label Phase IIb dose-finding, randomized, controlled study with a duration of 16 weeks of experimental therapy of Delpazolid(DZD) - Bedaquiline/Delamanid/ Moxifloxacin (BDM) in adult patients with newly diagnosed, smear positive, uncomplicated, drug sensitive pulmonary tuberculosis (TB) to evaluate the safety, efficacy, tolerability, pharmacokinetics and exposure/response-relationship of different doses of delpazolid in combination with bedaquiline, delamanid and moxifloxacin.

Participants will be randomized to one of five arms containing BDM standard dose with different doses of DZD.

Condition Pulmonary tuberculosis, Infection
Treatment Bedaquiline, Delamanid, Moxifloxacin, Delpazolid
Clinical Study IdentifierNCT04550832
SponsorLegoChem Biosciences, Inc
Last Modified on16 November 2021


Yes No Not Sure

Inclusion Criteria

Provide written, informed consent prior to all trial-related procedures including HIV testing
Male or female, aged between 18 and 65 years, inclusive
Body weight between 40 and 90 kg, inclusive
Newly diagnosed, previously untreated, drug susceptible pulmonary TB: presence of MTB complex and rapid molecular tests result confirming susceptibility to RIF and INH such as GeneXpert and/or HAIN MTBDR plus
A chest X-ray (no older than 2 weeks) which, in the opinion of the Investigator, is consistent with TB
Sputum positive on microscopy from concentrated sputum for acid-fast bacilli on at least one sputum sample (at least 1+ on the IUATLD/WHO scale)
The participant is willing to forgo consumption of foods high in tyramine for the period of taking study medication (See Appendix, section 20.2, page 92)
The participant is either unable to conceive/father children AND/OR his/her partner is unable to conceive/father children AND/OR they will consent to be using effective methods of contraception when engaging in heterosexual intercourse, as defined below
Non-childbearing potential: i. Female participant/sexual partner of male participant: Bilateral oophorectomy, and/or hysterectomy or bilateral tubal ligation more than 12 months ago and/or has been postmenopausal with a history of no menses for at least 12 consecutive months ii. Male participant/sexual partner of female participant: Vasectomised or has had a bilateral orchidectomy minimally three months prior to screening iii. Male participants having a pregnant female partner or a male sexual partner: At least one barrier method has to be used in this case. b. Effective contraception methods: i. Female participants: Two methods, including methods that the patient's sexual partner(s) use. At least one must be a barrier method. Contraception must be practised for at least until 12 weeks after the last dose of DZD. ii. Male participants: Two methods, including methods that the patient's female sexual partner(s) use. At least one must be a barrier method. Effective contraception must be ensured for at least 16 weeks after the last dose of DZD
Note: hormone-based contraception alone may not be reliable when taking RIF
during continuation phase; therefore, hormone-based contraceptives alone
cannot be used by female participants/female partners of male participants to
prevent pregnancy

Exclusion Criteria

Circumstances that raise doubt about free, unconstrained consent to study participation (e.g. prisoner or mentally handicapped person)
Poor general condition where delay in treatment cannot be tolerated or death within four months is likely
Poor social condition which would make it unlikely that the patient would be able to complete follow-up
The patient is pregnant or breast-feeding
The patient is infected with HIV with a CD4 count <220 cells/mm3. If >220 cells/mm3, patients will be included only if any of the following is applicable
The patient is antiretroviral (ARV) nave and able to postpone commencing HIV treatment for 2 months after the trial has started and then restrict regimens to those containing dolutegravir (see section 12.6.2 on ARVs) or The patient is ARV experienced (has been on ARVs a minimum of 5 months) and able to switch to a dolutegravir-based regimen
The patient is treated with nucleosidic reverse transcriptase inhibitors (are permitted as concomitant medication)
The patient is treated with protease inhibitors as part of antiretroviral treatment regimens, which will be stopped at least 3 days before the start of study treatment (WK01, day1) for a patient to be eligible
The patient is treated with Efavirenz as part of antiretroviral treatment regimens which would have to be stopped 14 days before the start of study treatment (WK00, Day 01) for a patient to be eligible
The patient has a known intolerance to any of the study drugs or concomitant disorders or conditions for which study drugs or standard TB treatment are contraindicated
The patient has a history of, or current evidence of clinically relevant cardiovascular metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or any other condition that will influence treatment response, study adherence or survival in the judgement of the investigator, especially
Neuropathy, or significant psychiatric disorder like depression or schizophrenia; especially if treatment for those has ever been required or is anticipated to be required
Clinically significant evidence of extra-pulmonary TB (e.g. miliary TB, TB meningitis, but not limited lymph node involvement)
Serious lung conditions other than TB, or significant respiratory impairment in the discretion of the investigator
Any diabetes mellitus
Cardiovascular disease such as myocardial infarction, heart failure, coronary heart disease, arrhythmia, tachyarrhythmia, or pulmonary hypertension
Arterial hypertension (systolic blood pressure 140 mmHg and/or diastolic blood pressure of 90 mmHg on two occasions during screening)
Long QT syndrome or family history of long QT syndrome or sudden death of unknown or cardiac-related cause
Alcohol or other drug abuse that is sufficient to significantly compromise the safety or cooperation of the patient, that includes substances prohibited by the protocol or has led to significant organ damage at the discretion of the investigator
Any of the following laboratory findings at screening
Serum amino aspartate transferase (AST) and/or alanine aminotransferase (ALT) >3x the upper limit of normal (ULN)
Serum alkaline phosphatase or y-glutamyl transferase > 2.5x the ULN
Serum total bilirubin level >1.5x the ULN
Estimated creatinine clearance (eCrCl; using the Cockroft and Gault formula [57] lower than 30 ml/min
Serum albumin < 2.8 mg/dl
Haemoglobin level <7.0 g/dl
Platelet count <50,000/mm3
Serum potassium below the lower level of normal for the laboratory
Blood glucose at screening of less than 70mg/dL (3.9mmol/L)
ECG findings in the screening ECG: (one or more)
QTcF of >0.450 s
Atrioventricular (AV) block with PR interval > 0.20 s
QRS complex > 120 milliseconds
Any other changes in the ECG that are clinically relevant as per discretion of the investigator
Restricted medication
Treatment with any other investigational drug within 1 month prior to enrolment or enrolment into other clinical (intervention) trials during participation
Previous anti-TB treatment with drugs active against MTB within the last 3 months prior to screening
Unable or unwilling to abide by the requirements regarding restricted medication or have taken restricted medication as described under section 12.6, page 58. Restricted medication includes the following drug classes
Anti-TB drugs other than study drugs
Medication that lowers the threshold for epileptic seizures
Medication that prolongs the QTc interval
Drugs that affect monoaminooxidase or serotonin metabolism
CYP 450 inhibitors or inducers, including grapefruit containing foods / beverages and St. John's Wort
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note